Background {#Sec1}
==========

Severe obstructive sleep apnea (OSA) is associated with an increased risk of cardiovascular (CV) disease, including coronary artery disease, heart failure, and stroke \[[@CR1]\]. Although often overlooked, mild OSA has been associated with a higher prevalence of CV disease and significant CV co-morbidities, including hypertension and carotid artery atherosclerosis \[[@CR2]--[@CR5]\]; although, other studies have not found an association of OSA with hypertension and CV diseases \[[@CR6]\]. As the severity of mild OSA tends to worse over time, active and effective treatment for mild OSA may be required \[[@CR7]\].

The vast majority of patients with mild OSA exhibit position-dependent apnea, in which the presence and severity of symptoms are related to body position, and the associated gravitational changes, during sleep \[[@CR8], [@CR9]\]. Specifically, gravity pulls the jaw and the tongue downwards while in the supine position, partially or fully obstructing the airway. Positional OSA is generally indicated by a total apnea-hypopnea index (AHI) ≥ 5, with a \> 50% reduction in the AHI between the supine and lateral positions, and an AHI that normalizes (AHI \< 5) in the lateral position \[[@CR9]\].

Various treatment modalities are available for mild OSA. Positional therapy, aimed at maintaining a non-supine sleep position, is often used as first-line treatment for patients with positional mild OSA, but has only moderate efficacy and poor compliance \[[@CR10]\]. Continuous positive airway pressure (CPAP) treatment significantly reduces the AHI and improves sleep efficiency in patients with OSA \[[@CR11]\]; however both patients with mild OSA and their clinicians are significantly less inclined to accept CPAP treatment \[[@CR11]\]. Mandibular advancement devices, while generally preferred by patients over CPAP, are not as effective in reducing sleep apnea symptoms as CPAP \[[@CR11]\]. In addition to its proven efficacy for improving apnea symptoms, effective CPAP treatment is associated with significantly decreased risks for cardiovascular disorders, including reduced arterial stiffness and decreased blood pressure (BP) in patients with OSA \[[@CR12]--[@CR14]\].

Few studies have examined BP and CPAP use in patients with positional-dependent mild OSA. Therefore, the primary aim of this study was to determine if there are differences in BP (including morning BP, evening BP, and the different in BP between evening and morning) between patients who have positional and non-positional mild OSA. We also evaluated patients with mild, moderate, and severe OSA. CPAP usage patterns in these patients were also evaluated.

Methods {#Sec2}
=======

Study subjects {#Sec3}
--------------

A total of 874 consecutive adult patients (aged ≥ 18 years) were screened in this retrospective cohort study. All were referred to the Chest and Sleep Clinic of Taipei Tzuchi Hospital, the Buddhist Tzuchi Medical Foundation (New Taipei City, Taiwan) for overnight polysomnography (PSG) for suspected OSA between January 2007 and December 2011. None of the subjects were previously diagnosed with OSA. Patients who underwent split-night sleep studies were excluded (n = 46) due to the inherent difficulty in separating the diagnostic and therapeutic portions of the study for postural effects \[[@CR15]\]. Patients with PSG results that did not include at least 15 minutes of data obtained in both supine and non-supine positions were also excluded (n = 352) \[[@CR15]\]. This time period was chosen with reference to a previous study \[[@CR15]\] and did not have to be consecutive. Patients with PSG results indicating non-apnea (AHI \< 5/h) were excluded (n = 103). We also excluded two patients whose PSG data was missing. The remaining 371 patients with OSA (AHI ≥ 5) were included in the final analyses. These 371 patients were divided into six groups by positional-dependency of OSA and the severity of OSA. Positional OSA was defined as a \> 50% reduction in the AHI between the supine and lateral positions and an AHI that normalized (AHI \< 5) in a non-supine sleep position. This study was approved by the Institutional Review Board of the Taipei Tzuchi Hospital, the Buddhist Tzuchi Medical Foundation. The informed patient consent was waived since this was retrospective study.

Measurements {#Sec4}
------------

### Anthropometric measurements and demographic data {#Sec5}

Medical history and anthropometric data were recorded prior to PSG study, and included body weight, height, body mass index (BMI), neck, waist, and hip circumference, waist-to-hip ratio, smoking status, hypertension, anti-hypertensive agents usage, and presence of CV diseases, defined as previous diagnosis of coronary artery disease (CAD) or a history of cerebrovascular accident (CVA).

### Sleep parameters {#Sec6}

Excessive daytime sleepiness was evaluated using the Chinese version of the Epworth Sleepiness Scale (ESS) before overnight PSG study \[[@CR16]\]. An attended, standard overnight PSG study was performed by trained sleep technicians at the sleep center. During PSG, electroencephalography (EEG), electrooculography, chin and bilateral anterior tibialis surface electromyography, electrocardiography, airflow through the nose and mouth (registered by thermistor), thoracoabdominal movements (registered by respiratory inductive plethysmography), position (by a sensor on the respiratory inductive plethysmography), snoring, and oxygen saturation (by pulse oximetry) were recorded. The PSG study lasted for at least 6 hours. PSG data were analyzed by manual scoring for every 30-second epoch by trained sleep technicians and were reviewed by sleep specialists.

Sleep stage was scored by trained sleep technicians using the standard criteria of Rechtschaffen and Kales \[[@CR17]\]. An apnea event was defined as an 80-100% reduction in airflow lasting for at least 10 seconds. A hypopnea event was defined as a reduction in airflow of at least 50% for at least 10 seconds or at least a 30% reduction in airflow for at least 10 seconds as compared with baseline and associated with at least 3% oxygen desaturation or with an EEG arousal. AHI was calculated from the total number of apnea and hypopnea events per hour of sleep. The desaturation index (DI) was defined as \> 3% oxygen desaturation per hour of sleep. The arousal index (AI) was defined as arousal episodes per hour of sleep \[[@CR18]\]. Sleep efficiency was defined as the fraction of total sleep time to total recording time. Sleep latency was defined as the time from lights off to the first identifiable sleep stage. Rapid eye movement (REM) latency was defined as the time from the first identifiable sleep stage to the first REM sleep.

### Blood pressure {#Sec7}

BP was measured with the patient in the supine position by trained technicians using an automated sphygmomanometer (Welch Allyn Vital Signs Monitor 300 Series) with an optimal cuff. The automated sphygmomanometer was regularly calibrated at least every year by the technician from the manufacturer who calibrated and/or validated the instrument against manual measurement performed with a standard mercury sphygmomanometer. Evening BP was measured after 15 minutes of rest and before sleep onset. Morning BP was measured immediately upon awakening with the patient attached to all PSG equipments. Two consecutive determinations were made on each occasion, separated by 5 minutes, and the results were averaged for both the evening and morning BP readings. Mean arterial blood pressure (MABP) was calculated using the systolic BP (SBP) and diastolic BP (DBP): MABP = 1/3 SBP + 2/3 DBP. Evening-to-morning BP difference was determined by: morning BP -- evening BP.

### CPAP acceptance and compliance {#Sec8}

All patients were offered treatment with CPAP. CPAP acceptance refers to the proportions of patients who meet the selection criteria for CPAP treatment and were willing to try CPAP and actually to use it at home \[[@CR19], [@CR20]\]. CPAP compliance refers to the proportions of patients using CPAP and delivering a pre-set level over a given time period \[[@CR19], [@CR20]\] Patients were routinely followed up every 3 months at the outpatient clinic. According to the policy of our sleep center, we routinely collected objective CPAP usage data (recorded by the device software) at each visit. The CPAP usage included percentage of days used, percentage of nights during which CPAP was used for ≥ 4 hours, and the overall mean hours used per night.

High CPAP compliance was defined as ≥ 4 hours of CPAP per night for ≥ 70% of the nights \[[@CR21]\]. Patients who did not meet these levels of CPAP usage were defined as having low CPAP compliance.

### Statistical analysis {#Sec9}

Results for continuous variables are presented as mean ± standard deviation, whereas results for categorical variables are presented as number (percentage). A Kolmogorov-Smirnov test was used to test for normality. Baseline characteristics between the positional OSA and non-positional OSA groups were compared by one-way analysis of variance (ANOVA) (continuous variables) or chi-square/Fisher's exact test (categorical variables). When significant results were revealed by ANOVA, post-hoc tests with Bonferroni correction or Dunnett's test were then carried out. Daytime sleepiness measurements, overnight polysomnography and blood pressure results among groups adjusting for baseline differences were estimated by linear regression models. All statistical assessments were evaluated at a two-sided alpha level of 0.05 using SAS software, version 9.2 (SAS Institute, Inc., Cary, NC, USA).

Results {#Sec10}
=======

Baseline characteristics and anthropometric measurements {#Sec11}
--------------------------------------------------------

The screening results are summarized in Figure [1](#Fig1){ref-type="fig"}. A total of 874 adult patients met the inclusion criteria for screening. Of these, 46 were excluded for undergoing split-night studies, 352 for not having sufficient data in both supine and non-supine sleep positions, 103 for having normal AHI, and 2 for missing PSG data.Figure 1**Flowchart of patient enrollment.** PSG: polysomnography; OSA: obstructive sleep apnea; AHI: apnea-hypopnea index.

The 371 patients who were included in the analysis were divided into six groups: non-positional mild OSA (group 1, n = 18), non-positional moderate OSA (group 2, n = 70), non-positional severe OSA (group 3, n = 178), positional mild OSA (group 4, n = 52), positional moderate OSA (group 5, n = 29), and positional severe OSA (group 6, n = 24).

The baseline characteristics of these six groups are summarized in Table [1](#Tab1){ref-type="table"}. Except for age, CAD and CVA, differences in gender, neck circumference, waist circumference and hip circumference, ratio of waist to hip, BMI, smoking history, CV co-morbidities, hypertension and anti-hypertensive drug use among groups were found. There were more males than females in the study with the highest proportion of males having severe OSA in both the non-positional and positional groups. Subjects with severe OSA in the non-positional subgroup had greater waist and hip circumference, higher waist-to-hip ratio, and BMI than the subjects with severe OSA than in the positional group. The neck circumference, waist circumference, and hip circumference in subjects with severe OSA (Group 3) in the non-position cohort were larger compared with those with mild (Group 1) or moderate (Group 2) OSA. There was no difference in these same variables across disease severity in the positional cohort. A similar percentage of patients had hypertension between the non-positional and positional cohort of subjects.Table 1**Baseline characteristics of patients with non-positional and positional obstructive sleep apnea**Non-positionalPositionalP-valueG1: MildG2: ModerateG3: SevereG4: MildG5: ModerateG6: Severe(n = 18)(n = 70)(n = 178)(n = 52)(n = 29)(n = 24)Age, years61.39 ± 15.2760.9 ± 13.0656.39 ± 13.5456.55 ± 13.254.76 ± 10.555.46 ± 13.950.999Gender0.011\*Female6(33.33%)25(35.71%)34(19.1%)^b^18(34.62%)6(20.69%)2(8.33%)^a^Male12(66.67%)45(64.29%)144(80.9%)34(65.38%)23(79.31%)22(91.67%)Neck circumference, cm37.83 ± 3.6338.22 ± 3.0540.55 ± 3.7^a,b^37.28 ± 3.0538.66 ± 2.7938.58 ± 2.62\<0.001\*Waist circumference, cm92.64 ± 10.6697.24 ± 9.08103.21 ± 11.67^a,b^91.99 ± 10.5995.71 ± 8.3492.64 ± 5.51^c^\<0.001\*Hip circumference, cm99.36 ± 9.95103.43 ± 9.31107.4 ± 10.55^a,b^100.73 ± 7.5102.71 ± 6.69100.02 ± 4.99^c^\<0.001\*Waist-to-hip ratio, %0.93 ± 0.060.94 ± 0.050.96 ± 0.050.91 ± 0.070.93 ± 0.050.92 ± 0.05^c^\<0.001\*BMI, kg/m^2^26.27 ± 4.7827.58 ± 4.7629.98 ± 5.1926.29 ± 3.4127.74 ± 2.9626.15 ± 2.78^c^\<0.001\*Smoking history0.017\*Past-smoker4(22.22%)14(20%)42(23.6%)9(17.31%)6(20.69%)11(45.83%)^a^Never smoked8(44.44%)46(65.71%)83(46.63%)34(65.38%)17(58.62%)11(45.83%)Current smoker6(33.33%)10(14.29%)53(29.78%)9(17.31%)6(20.69%)2(8.33%)CV co-morbiditiesAny CV co-morbidity11(61.11%)39(55.71%)113(63.48%)19(36.54%)15(51.72%)17(70.83%)^a^0.018\*HTN11(61.11%)38(54.29%)111(62.36%)18(34.62%)15(51.72%)16(66.67%)^a^0.015\*Anti-HTN drugs^†^11(100%)37(97.37%)89(80.18%)^b^18(100%)13(86.67%)14(87.5%)0.021\*Dosage of anti-HTN drugs (number of tablets /day)^†^2.23 ± 1.402.21 ± 1.151.98 ± 1.141.74 ± 1.241.35 ± 0.521.77 ± 0.920.192CAD0(0%)3(4.29%)13(7.3%)0(0%)1(3.45%)2(8.33%)0.394CVA2(11.11%)15(21.43%)32(17.98%)4(7.69%)6(20.69%)5(20.83%)0.307BMI: body mass index; CV: cardiovascular; HTN: hypertension; CAD: coronary artery disease; CVA: cerebrovascular accident.Results are mean ± standard deviation for continuous variables and number (percentage) for categorical variables.Intergroup comparisons were made by *analysis of variance* followed by Bonferroni correction or Dunnett's test for post-hoc test (continuous variables) or Chi-square / Fisher's exact tests (categorical variables).\*Indicates a significant between group difference, *P* \< 0.05.^†^Only HTN patients were analyzed.^a^Indicates significant difference from the mild subgroup within the nonpositional (or positional) group, *p* \< 0.05.^b^Indicates significant difference from the moderate subgroup within the nonpositional (or positional) group, *p* \< 0.05.^c^Indicates significant difference between the corresponding subgroups of nonpositional and positional groups, *p* \< 0.05.

Sleep parameters {#Sec12}
----------------

Table [2](#Tab2){ref-type="table"} summarizes the daytime sleepiness measurements and the overnight PSG results. ESS scores were not significantly different across groups. After adjusting for gender, waist-to-hip ratio, BMI, smoking and cardiovascular co-morbidity, significant associations were found for AHI, supine AHI, lateral AHI, DI, AI, S1, S2, REM, SaO~2~ mean, and SaO~2~ minimal (all *P* \< 0.001). Patients with non-positional severe OSA had higher AHI (55.98 ± 1.01 episodes/hour), supine AHI (66.11 ± 1.16 episodes/hours), lateral AHI (39.29 ± 1.35 episodes/hours) and lower SaO~2~ mean (90.65% ± 0.24%) than those with positional OSA. Within the non-positional group, group 3 had the largest values of the number of AHI, supine AHI, lateral AHI, DI, AI, and S1, followed by group 2 than group 1 who were similar in respect to the number of lateral AHI, DI, AI, and S1. S2, SaO~2~ mean, and SaO~2~ minimal in group 3 were smaller than those in the other two subgroups. In the positional group, the frequency of AHI and supine AHI were different among three subgroups in order of G6 \> G5 \> G4. The number of DI and AI in both group 4 and group 5 were smaller than those in the group 6. The SaO~2~ minimal was significantly different only between the group 4 and group 6.Table 2**Comparison of daytime sleepiness measurements, overnight polysomnography and blood pressure results for patients with non-positional and positional obstructive sleep apnea**Non-positionalPositionalAdjustedG1: MildG2: ModerateG3: SevereG4: MildG5: ModerateG6: Severe(n = 18)(n = 70)(n = 178)(n = 52)(n = 29)(n = 24)***P***-value ^1^**Daytime sleepiness measurements**  ESS score11.09 ± 1.319.91 ± 0.6611.06 ± 0.439.65 ± 0.810.55 ± 1.0210.24 ± 1.150.618**Overnight polysomnography**  AHI, episodes/hour12.68 ± 3.0624.41 ± 1.55^a^55.98 ± 1.01^a,b^11.93 ± 1.8621.97 ± 2.39^a^44.41 ± 2.69^a,b,c^\<0.001\*  Supine AHI, episodes/hour17.15 ± 3.5433.98 ± 1.80^a^66.11 ± 1.16^a,b^18.55 ± 2.1334.88 ± 2.76^a^54.55 ± 3.1^a,b,c^\<0.001\*  Lateral AHI, episodes/hour10.26 ± 4.1314.35 ± 2.1039.29 ± 1.35^a,b^3.73 ± 2.482.25 ± 3.22^c^5.17 ± 3.62^c^\<0.001\*  DI, episodes/hour7.07 ± 3.3815.12 ± 1.9545.62 ± 1.27^a,b^7.97 ± 2.3314.90 ± 3.0035.91 ± 3.37^a,b^\<0.001\*  AI, episodes/hour30.87 ± 3.6636.78 ± 1.8656.65 ± 1.21^a,b^19.50 ± 2.2327.91 ± 2.8646.99 ± 3.23^a,b^\<0.001\*  Sleep efficiency, %68.83 ± 3.6174.9 ± 1.8477.62 ± 1.1977.16 ± 2.278.46 ± 2.8278.48 ± 3.180.224  Sleep latency, minute28.85 ± 7.0627.53 ± 3.5922.3 ± 2.3323.64 ± 4.316.58 ± 5.5224.6 ± 6.220.601  REM latency, minute120.2 ± 17.1134.32 ± 8.83141.17 ± 5.7113.89 ± 10.29126.42 ± 12.99147.72 ± 15.250.238  S1, %22.22 ± 3.1824.01 ± 1.6236.19 ± 1.05^a,b^20.33 ± 1.9423.30 ± 2.4928.61 ± 2.8\<0.001\*  S2, %62.00 ± 3.1660.83 ± 1.6051.52 ± 1.04^a,b^60.52 ± 1.9259.14 ± 2.4757.84 ± 2.78\<0.001\*  S34, %3.18 ± 1.352.72 ± 0.692.5 ± 0.444.01 ± 0.824.13 ± 1.062.61 ± 1.190.560  REM, %12.60 ± 1.5412.43 ± 0.789.78 ± 0.5115.14 ± 0.9413.43 ± 1.2010.94 ± 1.35\<0.001\*  SaO~2~ mean, %92.92 ± 0.7393.23 ± 0.3790.65 ± 0.24^b^93.91 ± 0.4594.14 ± 0.5793.66 ± 0.65^c^\<0.001\*  SaO~2~ minimal, %86.36 ± 1.9081.22 ± 0.97^a^76.02 ± 0.63^a,b^84.56 ± 1.1781.87 ± 1.4976.96 ± 1.67^a^\<0.001\***Blood pressure**  Evening SBP, mmHg125.28 ± 3.43127.46 ± 1.74129.23 ± 1.13124.02 ± 2.09123.05 ± 2.68126.01 ± 3.020.176  Evening DBP, mmHg76.84 ± 2.4977.15 ± 1.2779.29 ± 0.8276.47 ± 1.5273.78 ± 1.9578.76 ± 2.190.138  Evening MABP, mmHg92.99 ± 2.6193.92 ± 1.3395.93 ± 0.8692.32 ± 1.5990.2 ± 2.0494.51 ± 2.30.119  Morning SBP, mmHg125.91 ± 3.27126.83 ± 1.66132.44 ± 1.08125.06 ± 1.99122.72 ± 2.56126.56 ± 2.880.002\*  Morning DBP, mmHg78.37 ± 2.8379.62 ± 1.4483.74 ± 0.93^b^79.06 ± 1.7277.32 ± 2.2180.81 ± 2.490.033\*  Morning MABP, mmHg94.23 ± 2.7995.35 ± 1.4299.97 ± 0.9294.39 ± 1.7092.47 ± 2.1896.07 ± 2.460.006\*  Evening-to-morning SBP difference, mmHg0.63 ± 2.67-0.63 ± 1.363.21 ± 0.881.04 ± 1.63-0.33 ± 2.090.54 ± 2.360.234  Evening-to-morning DBP difference, mmHg1.53 ± 2.152.47 ± 1.094.45 ± 0.712.59 ± 1.313.54 ± 1.682.05 ± 1.890.526  Evening-to-morning MABP difference, mmHg1.23 ± 2.111.43 ± 1.074.04 ± 0.72.07 ± 1.282.26 ± 1.651.55 ± 1.860.338ESS: Epworth Sleepiness Scale; AHI: apnea-hypopnea index; DI: desaturation index; AI: arousal index; REM: rapid eye movement; SaO2: oxygen saturation; SBP: systolic blood pressure; DBP: diastolic blood pressure; MABP: mean arterial blood pressure.Results are estimated mean ± standard deviation.\*Indicates a significant association, *P* \< 0.05.^1^After adjusting for gender, ratio of waist to hip, BMI, smoking, and cardiovascular comorbidity, associations between factors and groups were assessed by linear regression and *P*-values were estimated using Wald's test. Post-hoc testes were examined by Boferroni correction.^a^Indicates significant difference from the mild subgroup within the nonpositional (or positional) group, *p* \< 0.05.^b^Indicates significant difference from the moderate subgroup within the nonpositional (or positional) group, *p* \< 0.05.^c^Indicates significant difference between the corresponding subgroups of nonpositional and positional group, *p* \< 0.05.

Blood pressure {#Sec13}
--------------

As shown in Table [2](#Tab2){ref-type="table"}, morning BP differed across all groups (*P* = 0.002 for morning SBP, *P* =0.033 for morning DBP, *P* = 0.006 for morning MABP). BP was similar between non-positional and positional group; however, the morning DBP in the group 2 was lower compared with group 3.

CPAP acceptance and compliance {#Sec14}
------------------------------

Table [3](#Tab3){ref-type="table"} shows CPAP acceptance and compliance. Mild OSA patients showed the lowest CPAP acceptance rate (10%), followed by moderate group (37.37%) and severe group (61.88%, *P* \< 0.001). However, the significant difference in CPAP acceptance across OSA severity disappeared when the data was stratified by positional dependency. The duration of follow-up varied across groups ranging from 15.5 to 47 months.Table 3**Continuous positive airway pressure acceptance and compliance among patients with non-positional and positional obstructive sleep apnea**OutcomeMildModerateSevere***P***-value for comparison among severity levelsNon-positionalPositionalNon-positionalPositionalNon-positionalPositional(n = 18)(n = 52)(n = 70)(n = 29)(n = 178)(n = 24)CPAP acceptance by severity7 (10.00%)37 (37.37%)125 (61.88%)**\<0.001\***CPAP acceptance in each group1 (5.56%)6 (11.54%)26 (37.14%)11 (37.93%)110 (61.80%)15 (62.50%)CPAP compliance^1^0.896  High1 (100%)4 (66.67%)18 (69.23%)7 (63.64%)79 (71.81%)11 (73.33%)  Low0 (0%)2 (33.33%)8 (30.77%)4 (36.36%)31 (28.19%)4 (26.67%)Follow-up duration, months^1^47.0015.50 ± 9.5720.62 ± 15.5823.09 ± 19.5422.27 ± 15.5817.07 ± 14.68NACPAP: continuous positive airway pressure, NA: not available due to only one case in one group.Results are number (percentage) for categorical variables and mean ± standard deviation for continuous variables. Chi-square test or Fisher's exact test was implemented for categorical variables.^1^Statistics were derived from CPAP acceptors.

Discussion {#Sec15}
==========

This study found that positional mild OSA had less CV co-morbidities and non-positional moderate group had lower morning BP compared with severe OSA. In addition, OSA showed varying associations with sleep parameters depending upon severity and positional dependence. Patients with mild OSA had low CPAP acceptance but similar CPAP compliance compared with patients who had moderate or severe OSA. CPAP acceptance was not dependent on posture dependency of OSA.

The prevalence of positional OSA in our study among patients with mild OSA was 74.3% (52 of 70 mild OSA patients). This percentage is similar to that reported in a previous study using the same definitions for positional-dependency \[[@CR22]\]. Results of overnight PSG studies showed that patients with mild OSA in the positional group had lower AI and better sleep efficiency than the patients with mild OSA in the non-positional group, which also supports the results of a previous study \[[@CR8]\]. AI was within normal limits for our positional mild OSA group, but was higher than normal in the non-positional mild OSA group. Sleep efficiency was lower than normal in both groups. While associations between OSA and hypertension have been generally accepted, studies have also shown that sleep-disordered breathing, short sleep, and poor sleep have been associated with hypertension in the general population \[[@CR23]--[@CR25]\]. Therefore, patients experiencing poor sleep quality should receive optimal treatment (including surgery or CPAP), regardless of OSA severity or positional dependency in order to reduce the risk of developing hypertension.

The prevalence of hypertension in both mild OSA groups (61.1% of non-positional mild OSA and 34.6% of positional mild OSA patients) was similar to that reported in a previous study \[[@CR22]\] and was higher in both groups than the prevalence in general population \[[@CR26]\]. Much evidence supports elevated BP as a predictor of CV disease. Both increased SBP and increased DBP have been reported to be significant predictors of stroke and coronary artery disease \[[@CR27]\]. On average, SBP and DBP readings in the morning are 10%-20% lower than BP readings in the evening \[[@CR28]\]. A recent study showed that when this morning dip is replaced by a morning surge in patients with hypertension, the risk of developing a major CV event rises significantly \[[@CR29]\]. Ting et al. reported that elevated morning SBP was associated with significantly greater respiratory disturbances, blood glucose, and metabolic syndrome score \[[@CR30]\]. Many patients with OSA exhibit loss of the overnight dip in BP and exhibit morning BP elevations, possibly due to sympathetic nervous system over activity \[[@CR31], [@CR32]\]. In this study, patients in both the positional and non-positional groups showed a loss of evening to morning dip in BP, which supports the aforementioned findings. Our finding suggests that patients with positional mild OSA may have the same level of risk of developing CV disease as patients with non-positional mild OSA. These results suggest that there may be benefit in treating patients with mild OSA regardless of positional dependency. Well-designed randomized controlled trials are needed to directly further address these issues.

Several studies have documented that poor sleep quality is closely associated with hypertension \[[@CR23]--[@CR25]\]. There was no evidence that improving sleep lowers blood pressure, until recently. Huang et al. \[[@CR33]\] found that the blood pressure of poor sleepers was significantly reduced compared to pretreatment values following zolpidem (a non-benzodiazepine, non-hypotensive mild sedative with a short elimination half-life of 2.5 hrs) treatment (P \< 0.05) and more poor sleepers treated with zolpidem were converted from nondipping hypertension to dipping hypertension. Zolpidem treatment did not affect the blood pressure of good sleepers. Additional randomized controlled studies as necessary to further explore the potential that improving sleep, possibly through the use of CPAP, can reduce blood pressure.

Positional therapy is often relied upon as the primary treatment modality for positional mild OSA. A variety of strategies have been proposed for keeping patients in a non-supine position, including the use of tennis balls, vibrating positional alarms, and wearable devices \[[@CR34], [@CR35]\]. However, while positional therapy can moderately reduce AHI in some patients, long-term compliance with positional therapy is poor as outlined in recent reviews \[[@CR10], [@CR36]\]. In addition, since CPAP clearly provides superior improvement over positional therapy, positional therapy is not recommended for first-line treatment of OSA \[[@CR10]\].

The efficacy of CPAP in reducing apnea symptoms and the risk of CV disorders has been clearly demonstrated, making it the treatment of choice for patients with OSA; however, patients are often reluctant to accept CPAP treatment due to perceived inconvenience and discomfort \[[@CR37]\]. Unsurprisingly, few patients in our study were willing to start CPAP treatment, especially in the mild OSA patients (10%). However, the overall CPAP acceptance of all the patients was 45.6%, and for patients with mild OSA was 10%. The low acceptance rate may, in part reflect the small sample size and the fact that in Taiwan, the cost of CPAP is not covered by national or commercial insurance and is paid out-of-pocket by the patient and is 2--3 times higher than that in other countries \[[@CR38]\]. Acceptance rates from other studies range from 40-90% \[[@CR38]--[@CR45]\]. In the studies in which the acceptance rate is higher (about 70%), often CPAP is free to subject participating in these trials \[[@CR42]--[@CR45]\]. Other reasons that may have affected the acceptance rate are that the retrospective study design is closer to the real-world setting and that the strong national health insurance and healthcare in Taiwan is so convenient and inexpensive that the Taiwanese pay little attention on health maintenance. Overall CPAP compliance of our patients was 71.4% (120 out of 168 patients) and is comparable with that found in studies in Europe and US which were about 75% and 46%, respectively \[[@CR42], [@CR43], [@CR46]--[@CR49]\]. Reasons for the wide range of compliance across countries include different definition of compliance and different sources of CPAP. Moreover, free CPAP in prospective studies results in higher compliance, while out-of-pocket CPAP in retrospective studies results in lower compliance. Nonetheless, the majority of our patients who accepted CPAP treatment showed a high level of compliance. Thus, educational support and physician involvement to increase patient awareness of the increased CV risks, even with mild OSA, and the potential benefits of CPAP treatment for CV health might improve patient acceptance and compliance \[[@CR41]\].

There is growing evidence supporting the use of CPAP in sleepy patients with mild OSA \[[@CR50]\], however, the findings are mixed and CPAP treatment of mild OSA is recommended as only a treatment option \[[@CR51]\]. Given the findings that there is an association of mild OSA with hypertension and mild OSA tends to worse over time, we suggest that CPAP treatment may benefit these patients. However, further randomized controlled studies are required to better understand the potential benefit of CPAP in treating mild OSA and hypertension.

This study is limited by the retrospective design and the small number of patients included. Larger controlled studies are warranted to further study the effects of positional dependency on BP, and CPAP efficacy and usage patterns in patients with OSA. Besides, we used a thermistor (not nasal pressure transducer to detect airflow and not an esophageal pressure sensor to detect respiratory effort related arousal). These may result in an under-estimation of the severity of OSA and consequently misclassification of some patients in the mild and moderate OSA groups.

Conclusion {#Sec16}
==========

This study found that positional mild OSA had less cardiovascular co-morbidities and non-positional moderate OSA had lower morning blood pressure compared with severe group. CPAP acceptance by patients with mild OSA was low, but CPAP compliance was similar to that of patients with moderate or severe OSA. CPAP acceptance rate was independent of posture dependency of OSA. Since there is increasing evidences of greater cardiovascular risk for untreated mild OSA, optimal treatment (including CPAP or surgery) for mild OSA regardless of posture dependency is critical. Strategies to improving CPAP acceptance among mild OSA patients will be the issue in the future.
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